Optimal strategy of treatment of Helicobacter pylori infection: renaissance of antisecretory drugs?
Nijevitch
A A
AA
Farztdinov
K M
KM
Sataev
V U
VU
Dashkova
S
S
Kazykhanov
N S
NS
D001729:Bismuth / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D011899:Ranitidine / Q000031:analogs & derivatives / Q000627:therapeutic use*
D006635:Histamine H2 Antagonists; C073340:ranitidine bismuth citrate; D011899:Ranitidine; D001729:Bismuth